ɬÀï·¬

Journal News

Finasteride may cut heart disease risk

Research on common hair loss and prostate drug shows results in men and mice
Lauren   Quinn
By Lauren Quinn
March 4, 2024

The drug finasteride, also known as Propecia or Proscar, treats male pattern baldness and enlarged prostate in millions of men worldwide. But a new  study suggests the drug may also provide a surprising and life-saving benefit: lowering cholesterol and cutting the overall risk of cardiovascular disease. 

The study, published in the , found significant correlations between finasteride use and lower cholesterol levels in men taking part in the National Health and Nutrition Examination Survey between 2009 and 2016. In mice taking high finasteride doses, the researchers found reductions in total plasma cholesterol, delayed atherosclerosis progression, lower inflammation in the liver, and related benefits. 

Jaume Armangual and Donald Molina Chaves in front of their poster
Courtesy of Donald Molina Chaves
Ph.D. student Donald Molina Chaves, right, was one of the first authors on the study completed in the lab of Jaume Amengual, left, an assistant professor of personalized nutrition at the College of Agricultural, Consumer and Environmental Science, University of Illinois Urbana Champaign.

“When we looked at the men taking finasteride in the survey, their cholesterol levels averaged 30 points lower than men not taking the drug. I thought we’d see the opposite pattern, so it was very interesting,” said lead study author , assistant professor in the  and the , both part of the  (ACES) at U. of I. 

As exciting as the survey results were, they had their limitations. Of nearly 4,800 survey respondents meeting general health criteria for inclusion in the analysis, only 155, all men over 50, reported using finasteride. And the researchers couldn’t tell how much or how long men in the survey had taken the drug. 

“This was not a clinical study in which you can control everything perfectly,” Amengual said. “It was more of an observation that led us to say, ‘Okay, now we've seen this in people. Let's see what happens in mice.’”

But first, why would a hair loss and prostate drug affect cholesterol? Amengual studies atherosclerosis, the condition in which cholesterol plaques choke arteries, leading to stroke, heart attack, and other forms of cardiovascular disease. Because the disease is far more common in men than premenopausal women, scientists have long suspected the sex hormone testosterone is important in atherosclerosis, though its role isn’t entirely clear.   

Finasteride works by blocking a protein found in hair follicles and the prostate gland that activates testosterone. The common thread, testosterone, was enough to pique Amengual’s interest. 

“I was reading about this medication one day, and I started to notice that there were not many long-term studies of the implications of the drug. Initially, it was just my own curiosity, based on the fact that hormone levels are known to have an effect on atherosclerosis, hair loss, and prostate issues,” he said. “So, we decided to dig into it.” 

After documenting the first-ever link, albeit observational, between finasteride and lower cholesterol in men, Amengual got doctoral student  to see if the pattern held in mice.

Molina Chaves tested four levels of finasteride — 0, 10, 100, and 1000 milligrams per kilogram of food — in male mice genetically predisposed to atherosclerosis. The mice consumed the drug, along with a high-fat, high-cholesterol “Western” diet, for 12 weeks. After the experiment, Molina Chaves analyzed the levels of cholesterol and other lipids in the mice, along with evidence of atherosclerotic plaques. He also tested gene expression in the liver, looked at bile acid metabolism, and analyzed steroids, triglycerides, immune activity, and more.

“Mice that were given a high dose of finasteride showed lower cholesterol levels within the plasma as well as in the arteries,” Molina Chaves said. “There were also fewer lipids and inflammatory markers in the liver.” 

Although the effects were only significant at the highest dose, a level Amengual calls outrageous for humans, he explains that mice metabolize finasteride differently than people. 

“It's an incredibly high level of the drug. But we use mice as a model, and they are extremely resistant to things that would kill any of us,” he said. “So it is not that crazy when you think about it that way.”  

Humans take 1 milligram or 5 milligram doses of finasteride daily for hair loss and enlarged prostate, respectively. The fact that a clear pattern showed up in a survey of men likely taking one of these doses suggests the drug may be lowering cholesterol without the megadoses tested in mice. 

The next step is for physicians to start tracking cholesterol in finasteride patients or conduct a clinical trial to verify the effect. Amengual says it may be especially important to understand how finasteride affects trans individuals.

“Over the past decade, doctors have started prescribing this drug for individuals transitioning either from male to female or female to male. In both cases, the hormonal changes can trigger hair loss,” he said. “The interesting thing is that transgender people are also at a higher risk of cardiovascular diseases. So this drug could have a potential beneficial effect to prevent cardiovascular disease not only in cis men, but also in transgender individuals.”

Finally, Amengual notes, like any medication, finasteride is not without risk. People should consult their doctors to learn more.

This article was originally published by on NewsWise by the University of Illinois Urbana Champlain. Read the original .
 

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Lauren   Quinn
Lauren Quinn

Lauren Quinn is the assistant director of communications in the College of Agricultural, Consumer and Environmental Sciences at the University of Illinois Urbana-Champaign.
 

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Targeting toxins to treat whooping cough
Journal News

Targeting toxins to treat whooping cough

May 1, 2025

Scientists find that liver protein inhibits of pertussis toxin, offering a potential new treatment for bacterial respiratory disease. Read more about this recent study from the Journal of Biological Chemistry.

Elusive zebrafish enzyme in lipid secretion
Journal News

Elusive zebrafish enzyme in lipid secretion

May 1, 2025

Scientists discover that triacylglycerol synthesis enzyme drives lipoproteins secretion rather than lipid droplet storage. Read more about this recent study from the Journal of Biological Chemistry.

Scientists identify pan-cancer biomarkers
Journal News

Scientists identify pan-cancer biomarkers

April 30, 2025

Researchers analyze protein and RNA data across 13 cancer types to find similarities that could improve cancer staging, prognosis and treatment strategies. Read about this recent article published in Molecular & Cellular Proteomics.

New mass spectrometry tool accurately identifies bacteria
Journal News

New mass spectrometry tool accurately identifies bacteria

April 30, 2025

Scientists develop a software tool to categorize microbe species and antibiotic resistance markers to aid clinical and environmental research. Read about this recent article published in Molecular & Cellular Proteomics.

New tool matches microbial and metabolic metaproteomic data
Journal News

New tool matches microbial and metabolic metaproteomic data

April 30, 2025

Scientists develop a bioinformatics program that maps omics data to metabolic pathways. Read about this recent article published in Molecular & Cellular Proteomics

Meet Paul Shapiro
Interview

Meet Paul Shapiro

April 29, 2025

Learn how the JBC associate editor went from milking cows on a dairy farm to analyzing kinases in the lab.